Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.55 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | HTR1B | P28222 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | ESRRB | O95718 | 2/20 | 0.36 |
| ▸ | ESRRG | P62508 | 2/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483001 | 0.81 | ADRB1 (0.55) | ADRB1HTR1AHTR7HTR2BHTR6 | |
| SCHEMBL6094315 | 0.81 | QDPR (0.39) | ADRB1HTR5AESRRBESRRGMAPT | |
| SCHEMBL4094720 | 0.81 | HTR7 (0.39) | ADRB1HTR1AHTR1DHTR7HTR2B | |
| SCHEMBL2410875 | 0.80 | ADRB1 (0.59) | ADRB1HTR1AHTR1DHTR1BHTR7 | |
| SCHEMBL3482596 | 0.80 | ADRB1 (0.59) | ADRB1HTR1AHTR7MAPTLMNA | |
| SCHEMBL739058 | 0.80 | SIGMAR1 (0.52) | ADRB1HTR1AHTR7HTR2BHTR6 | |
| SCHEMBL3537094 | 0.78 | PLD1 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C9ADRB2 | |
| SCHEMBL6956749 | 0.78 | KDM4E (0.43) | KCNH2 | |
| SCHEMBL6094131 | 0.78 | ALDH1A1 (0.47) | MAPTL3MBTL1CYP3A4ALDH1A1 | |
| SCHEMBL18278509 | 0.74 | ADRB1 (0.36) | ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040249147-A1 | Synthesis of key azole-antifungal intermediates | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | US | disclosed |
| EP-1432704-A1 | SYNTHESIS OF KEY AZOLE-ANTIFUNGAL INTERMEDIATES | RANBAXY LABORATORIES, LTD. (IN) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027103-A1 | SYNTHESIS OF KEY AZOLE-ANTIFUNGAL INTERMEDIATES | RANBAXY LABORATORIES LIMITED (IN) | 2003-04-03 | — | — | WO | disclosed |
| EP-0454501-B1 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | SANKYO CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| EP-0839812-A1 | Preparation of benzylthiazolidine derivatives | Sankyo Company Limited (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5387596-A | Treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0454501-A2 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | Sankyo Company Limited (JP) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249147-A1 | Synthesis of key azole-antifungal intermediates | ERG28, CYP11B1, CYP2E1 | ADRB1 2635/4885HTR1A 4158/4885HTR1D 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.